UFR des Sciences Pharmaceutiques et Biologiques, Nantes, France Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2016
NCT02868177
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

totum-63 (1 trial)

Drugs in Phase 2 Trials (2)

val070-a (1 trial)

val070-b (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 3)

Glucose Intolerance (Phase 3)

Hypercholesterolemia (Phase 2)

Hypertriglyceridemia (Phase 3)

Insulin Resistance (Phase 3)

Obesity (Phase 3)

Prediabetic State (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 3